Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
675 participants
INTERVENTIONAL
2008-12-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
NCT02710708
Efficacy and Safety Oral Contraceptive Study
NCT00185484
GA YAZ ACNE in China Phase III
NCT00818519
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
NCT00824187
A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception
NCT00185419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
YAZ (SH T00186, BAY86-5300)
20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YAZ (SH T00186, BAY86-5300)
20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smokers may not exceed 30 years of age.
Exclusion Criteria
* Pregnancy, lactation (less than 3 menstrual cycles since delivery, abortion or lactation before start of treatment)
* Menstrual disorders suspicious of ovarian failure (e.g. oligomenorrhea, amenorrhea, hypomenorrhea
* Any disease or condition that may worsen under hormonal treatment
* Other contraceptive methods such as sterilization or IUD/IUS
* Substantial overweight (BMI \> 30 kg/m2).
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer Healthcare AG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Wuhan, Hubei, China
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Yangzhou, Jiangsu, China
Shenyang, Liaoning, China
Jinan, Shandong, China
Xi’an, Shanxi, China
Chengdu, Sichuan, China
Beijing, , China
Beijing, , China
Chongqing, , China
Chongqing, , China
Shanghai, , China
Shanghai, , China
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
311041
Identifier Type: OTHER
Identifier Source: secondary_id
91619
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.